Rafael Holdings, Inc. Class B RFL 深 滬
已收盤 02-06 16:00:00 美东时间
1.22
+0.040
+3.39%
華盛通- 最 高1.27
- 今 開1.22
- 成交量 10.27万股
- 最 低 1.2001
- 昨 收 1.18
- 總市值 6315.06万
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 1.12
- 委 比 0.00%
- 總股本 5176.28万
- 歷史最高 65.5004
- 量 比 1.26
- 振 幅 5.92%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rafael Holdings Appoints Alan Grayson to Board
Rafael Holdings ( ($RFL) ) has shared an update. On October 23, 2025, Rafael Ho...
2025-10-29 04:28
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
<p>Rafael Holdings, Inc. announced the passing of Lead Independent Director Stephen Greenberg and the appointment of Alan Grayson to the Board of Directors. Alan will join the Compensation, Corporate Governance, and Nominating Committees. Markus Sieger, an existing Board member, will lead the Audit Committee and assume the role of Lead Independent Director. The company also highlighted its lead product candidate, Trappsol® Cyclo™, under Phase 3 c...
2025-10-28 20:01
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
Rafael Holdings announced Phase 3 data for Trappsol Cyclo™ in NPC1 patients under 3. At 48 weeks, 7/9 patients showed CGI-S improvement or stabilization. 96-week study ongoing with 94 patients globally. No SAEs linked to drug. Data presented at ICIEM 2025.
2025-09-16 12:00
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, has had two abstracts selected for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The presentations will highlight Trappsol® Cyclo™'s efficacy and safety in treating Niemann-Pick Disease Type C1 (NPC1) based on clinical studies and an expanded access program. The oral presentation, led by Dr. Caroline Hastings, will di...
2025-08-27 12:00
Rafael Holdings Announces Executive Team Changes
The latest update is out from Rafael Holdings ( ($RFL) ). On August 4, 2025, Ra...
2025-08-08 05:47
Rafael Holdings Elects N. Scott Fine as Vice Chairman
Rafael Holdings ( ($RFL) ) has shared an update. On July 14, 2025, Rafael Holdi...
2025-07-18 20:57
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Rafael Holdings announced that its subsidiary Cyclo Therapeutics' 96-week pivotal phase 3 TransportNPC study evaluating intravenous Trappsol® Cyclo™ for the potential treatment of Niemann-Pick Disease Type C1 (NPC1) will continue following a favorable interim analysis by an independent Data Monitoring Committee (DMC) and FDA acceptance of the statistical analysis plan. TrappsolCyclo has shown a favorable safety profile in phase 1, 2, and ongoing ...
2025-06-18 11:00
Rafael Holdings shares are trading lower. The company reported Q3 financial results.
Rafael Holdings shares are trading lower. The company reported Q3 financial res...
2025-06-12 00:49
Rafael Holdings Q3 EPS $(0.19) Up From $(1.36) YoY, Sales $362.00K Up From $336.00K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 86.03 percent increase over losses of $(1.36) per share from the same period last year. The company reported $362.00 thousand in sales
2025-06-11 19:24
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rafael Holdings, Inc. completed a $25 million rights offering, raising $4.007 million through 3.13 million Class B shares at $1.28 each. Howard Jonas, CEO, and affiliates initially holding 32% of shares did not exercise their rights due to a backstop commitment, purchasing unsubscribed shares for $20.99 million. The offering and backstop placement total $24.9 million net proceeds, supporting regulatory efforts and potential launch of Trappsol Cyc...
2025-06-04 20:01
